151 related articles for article (PubMed ID: 37729184)
1. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Fujikawa K; Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
PLoS One; 2023; 18(9):e0291772. PubMed ID: 37729184
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.
Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Nishikawa H; Nakajima J; Seto Y; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
Nagoya J Med Sci; 2021 Nov; 83(4):827-840. PubMed ID: 34916725
[TBL] [Abstract][Full Text] [Related]
3. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract][Full Text] [Related]
4. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
5. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
6. Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma.
Ono S; Suzuki S; Kondo Y; Okubo I; Goto M; Ogawa T; Kato H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Nagao T; Ueda R
Sci Rep; 2022 Dec; 12(1):21678. PubMed ID: 36522365
[TBL] [Abstract][Full Text] [Related]
7. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
Zamarin D; Hamid O; Nayak-Kapoor A; Sahebjam S; Sznol M; Collaku A; Fox FE; Marshall MA; Hong DS
Clin Cancer Res; 2020 Sep; 26(17):4531-4541. PubMed ID: 32586937
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
9. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
12. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
[TBL] [Abstract][Full Text] [Related]
13. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
14. [Basic and clinical evaluation of anti-CCR4 mAb in cancer immunotherapy].
Oka M; Kurose K
Nihon Rinsho; 2017 Feb; 75(2):209-215. PubMed ID: 30562854
[TBL] [Abstract][Full Text] [Related]
15. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
16. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
17. Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia.
Ureshino H; Shindo T; Nishikawa H; Watanabe N; Watanabe E; Satoh N; Kitaura K; Kitamura H; Doi K; Nagase K; Kimura H; Samukawa M; Kusunoki S; Miyahara M; Shin-I T; Suzuki R; Sakaguchi S; Kimura S
Cancer Immunol Res; 2016 Aug; 4(8):644-9. PubMed ID: 27215229
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
20. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
